Other antiretroviral studies at ICAAC
26 December 2008. Related: Conference reports, Antiretrovirals.
Antiretrovirals
Non alcoholic fatty liver disease (NAFLD) is common among HIV-positive patients
26 December 2008. Related: Conference reports, Antiretrovirals.
FDA approves new paediatric AZT dosing
26 December 2008. Related: Antiretrovirals.
US revisions to darunavir label include once-daily indication for naive patients
26 December 2008. Related: Antiretrovirals.
Baseline renal insufficiency and mortality risk in HIV-positive adults in Zambia
26 December 2008. Related: Antiretrovirals.
Inflammatory and coagulation biomarkers linked to mortality in large treatment interruption trial
26 December 2008. Related: Antiretrovirals.
Abacavir and heart disease: SMART study supports an abacavir-associated increased risk of cardiovascular disease
30 October 2008. Related: Conference reports, Antiretrovirals, Side effects.
EMEA state that animal studies support no increased risk of malignancy from contamination of nelfinavir (Viracept) with ethyl mesilate (EMS)
30 October 2008. Related: Antiretrovirals, Side effects.
Antiretrovirals calculated to extend life expectancy by 35 years
30 October 2008. Related: Antiretrovirals.
Etravirine approved in Europe
30 October 2008. Related: Antiretrovirals.
Abacavir label updated in the US on use of B-5701 testing and cardiovascular risk
30 October 2008. Related: Antiretrovirals.
Ritonavir label updated in the US relating to cardiac arrhythmia reported in high-dose studies
30 October 2008. Related: Antiretrovirals, Side effects.
Atazanavir label updated in the US relating to drug interactions with NNTRIs, hormonal contraceptives, midazolam, H2 receptor antagonists and other drugs
30 October 2008. Related: Antiretrovirals.
Pipeline antiretrovirals: IDX899, CHX157 and bevirimat
30 August 2008. Related: Conference reports, Antiretrovirals.
Renal tubular dysfunction with tenofovir-based HAART in four vertically infected adolescents
30 August 2008. Related: Conference reports, Antiretrovirals.
Boosted atazanavir approved in Europe as first-line therapy
30 August 2008. Related: Antiretrovirals.
BMS and Merck discontinue 100mg capsule formulation of efavirenz used for paediatric treatment
30 August 2008. Related: Antiretrovirals.
Saquinavir (Invirase) interactions with digoxin, garlic capsules, methadone, tipranavir and omeprazole: US label changes
30 August 2008. Related: Antiretrovirals.
US label changes for nevirapine paediatric solution
30 August 2008. Related: Antiretrovirals.
New US pediatric dosing for lopinavir/r
30 August 2008. Related: Antiretrovirals.
New US pediatric dosing for tipranavir/r
30 August 2008. Related: Antiretrovirals.
DSMB stops ACTG study due to suboptimal responses
30 August 2008. Related: Antiretrovirals.
Tibotec issue Dear Doctor letter and FDA require darunavir label change relating to hepatotoxicity
12 June 2008. Related: Antiretrovirals.
Atazanavir 300mg capsule available
12 June 2008. Related: Antiretrovirals.
Raltegravir approved in Scotland
12 June 2008. Related: Antiretrovirals.
Abacavir, ddI and risk of heart attack: additional published data and statements from the EMEA and FDA
1 June 2008. Related: Antiretrovirals.
Atazanavir/r vs lopinavir/r in treatment-naive patients: 48 week results
1 April 2008. Related: Conference reports, Antiretrovirals.
FDA approve 600mg darunavir tablet
1 April 2008. Related: Antiretrovirals.
US study changes use of abacavir/3TC in naive patients with viral load >100,000 copies based on DSMB recommendation
1 April 2008. Related: Antiretrovirals.
Boehringer fails to register tipranavir in Brazil after using Brazilian patients in registrational study
1 February 2008. Related: Antiretrovirals, Treatment access.
Raltegravir approved in Europe and available in the UK
1 February 2008. Related: Antiretrovirals.
Paediatric lopinavir/r receives positive opinion from EMEA
1 February 2008. Related: Antiretrovirals.
Etravirine (TMC-125) approved in the US
1 February 2008. Related: Antiretrovirals.
Changes to atazanavir product label in US
1 February 2008. Related: Antiretrovirals.
HIV-positive adults with CD4 >500 cells/mm3 have similar mortality rates as the general population after seven years ARV treatment
1 February 2008. Related: Antiretrovirals.
Saquinavir/r non-inferior to Kaletra at week 48 (Gemini study)
2 December 2007. Related: Conference reports, Antiretrovirals.
Darunavir once-daily is non-inferior to lopinavir/r in treatment-naive patients at 48 weeks (Artemis study)
2 December 2007. Related: Conference reports, Antiretrovirals.
Half-dose Kaletra tablet approved for paediatric use in the US
1 December 2007. Related: Antiretrovirals, Paediatric care.
Atripla approved in Europe as switch option for suppressed patients
2 October 2007. Related: Antiretrovirals.
Maraviroc approved in Europe for treatment-experienced CCR5-tropic patients
2 October 2007. Related: Antiretrovirals.
Paediatric formulation of fosamprenavir approved in Europe
2 October 2007. Related: Antiretrovirals.
Raltegravir approved in the US
2 October 2007. Related: Antiretrovirals.
EMEA recommends reinstating license for Roches nelfinavir
2 October 2007. Related: Antiretrovirals.
Roche withdraw application for Biojector needle-free option for T-20
2 October 2007. Related: Antiretrovirals.
Darunavir/r shows superiority over lopinavir/r at 48 weeks in TITAN trial
3 September 2007. Related: Conference reports, Antiretrovirals.
Maraviroc fails to show non-inferiority to efavirenz in treatment-naive patients: 48 week results
3 September 2007. Related: Conference reports, Antiretrovirals.
Importance of using maraviroc in combination with other active drugs in treatment-experienced patients
3 September 2007. Related: Conference reports, Antiretrovirals.
Week 48 raltegravir results in treatment-naive phase II dose-finding study
3 September 2007. Related: Conference reports, Antiretrovirals.
DUET studies clarify antiviral efficacy of etravirine and cross-resistance profile to other NNRTIs
3 September 2007. Related: Conference reports, Antiretrovirals.
Boosting atazanavir in treatment-naive patients, and impact on lipids after switching from lopinavir/r
3 September 2007. Related: Conference reports, Antiretrovirals.
Saquinavir/r vs lopinavir/r in treatment-naive patients
3 September 2007. Related: Conference reports, Antiretrovirals.
Fosamprenavir/r vs atazanvir/r in treatment-naive patients
3 September 2007. Related: Conference reports, Antiretrovirals.
Maraviroc approved in the US
3 September 2007. Related: Antiretrovirals.
Monogram launches Trofile HIV co-receptor tropism test
3 September 2007. Related: Antiretrovirals.
Raltegravir (MK-0518) phase 3 trials show successful viral suppression in multi-drug resistant patients
4 April 2007. Related: Conference reports, Antiretrovirals, Drug resistance.
Maraviroc phase 2b/3 results in treatment experienced CCR5-tropic patients
4 April 2007. Related: Conference reports, Antiretrovirals.
Phase 2 study of Gileads integrase inhibitor elvitegravir (GS-9137)
4 April 2007. Related: Conference reports, Antiretrovirals.
Phase 2b study comparing rilpivirine (TMC-278) to efavirenz in treatment-naive patients: 48-week results
4 April 2007. Related: Conference reports, Antiretrovirals.
PK results from heat-stable formulation of ritonavir
4 April 2007. Related: Conference reports, Antiretrovirals.
Use of low-dose rapamycin, a CCR5 suppressant, to increase potency of T-20 in vitro
4 April 2007. Related: Conference reports, Antiretrovirals.
Darunavir (TMC-114) approved in Europe
4 April 2007. Related: Antiretrovirals.
No significant interaction reported between etravirine (TMC125) and raltegravir (MK-0518)
4 April 2007. Related: Antiretrovirals.
Future of second-generation fusion inhibitors less certain as Trimeris and Roche separate
4 April 2007. Related: Antiretrovirals.
Pharmacokinetic study of Triomune-40 in Malawi: higher d4T exposure suggests importance of using lower dose formulations of d4T
5 February 2007. Related: Antiretrovirals.
GSK stops development of brecanavir
5 February 2007. Related: Antiretrovirals.